Cogent Biosciences, Inc.COGTNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank30
3Y CAGR-48.6%
5Y CAGR-24.8%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-48.6%/yr
vs +42.7%/yr prior
5Y CAGR
-24.8%/yr
Recent deceleration
Acceleration
-91.3pp
Decelerating
Percentile
P30
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
3 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 15.96% |
| 2024 | 33.90% |
| 2023 | 42.86% |
| 2022 | 117.53% |
| 2021 | -23.04% |
| 2020 | 66.21% |
| 2019 | 14.17% |
| 2018 | 28.34% |
| 2017 | 35.65% |
| 2016 | 220.96% |